Bendamustyna: interakcje
Bendamustyna (Treanda, Bendeka, Belrapzo): 91 udokumentowanych interakcji w indeksowanych przez nas etykietach FDA i kartach informacyjnych. Poważne: 2, umiarkowane: 89, niewielkie: 0, pary, dla których etykieta nie zgłasza istotnej interakcji: 0. Każda pozycja poniżej cytuje zdanie, na którym się opiera. Ta strona leku to punkt wyjścia, a nie rozstrzygnięcie dla indywidualnej sytuacji.
Interakcje z etykiety
Poważne interakcje (2)
However, there may be an increased risk of severe skin toxicity when bendamustine hydrochloride and allopurinol are administered concomitantly. [see Warnings and Precautions (5.6) ] 5.6 Skin Reactions Fatal and serious skin reactions have been reported with bendamustine hydrochloride injection treatment in clinical trials and postmarketing safety reports, including… (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Progressive Multifocal Leukoencephalopathy (PML) Progressive multifocal leukoencephalopathy (PML), including fatal cases, have occurred following treatment with bendamustine, primarily in combination with rituximab or obinutuzumab [see Adverse Reactions (6.2) ] . (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Umiarkowane interakcje (89)
Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Effect of Other Drugs on Bendamustine Hydrochloride Injection CYP1A2 Inhibitors The coadministration of Bendamustine Hydrochloride Injection with CYP1A2 inhibitors may increase bendamustine plasma concentrations and may result in increased incidence of adverse reactions with Bendamustine Hydrochloride Injection [see Clinical Pharmacology (12.3) ] . (etykieta leku Bendamustyna, Interakcje z innymi lekami)
Effect of Other Drugs on Bendamustine Hydrochloride Injection CYP1A2 Inhibitors The coadministration of Bendamustine Hydrochloride Injection with CYP1A2 inhibitors may increase bendamustine plasma concentrations and may result in increased incidence of adverse reactions with Bendamustine Hydrochloride Injection [see Clinical Pharmacology (12.3) ] . (etykieta leku Bendamustyna, Interakcje z innymi lekami)
Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Effect of Other Drugs on Bendamustine Hydrochloride Injection CYP1A2 Inhibitors The coadministration of Bendamustine Hydrochloride Injection with CYP1A2 inhibitors may increase bendamustine plasma concentrations and may result in increased incidence of adverse reactions with Bendamustine Hydrochloride Injection [see Clinical Pharmacology (12.3) ] . (etykieta leku Bendamustyna, Interakcje z innymi lekami)
Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Effect of Other Drugs on Bendamustine Hydrochloride Injection CYP1A2 Inhibitors The coadministration of Bendamustine Hydrochloride Injection with CYP1A2 inhibitors may increase bendamustine plasma concentrations and may result in increased incidence of adverse reactions with Bendamustine Hydrochloride Injection [see Clinical Pharmacology (12.3) ] . (etykieta leku Bendamustyna, Interakcje z innymi lekami)
Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Effect of Other Drugs on Bendamustine Hydrochloride Injection CYP1A2 Inhibitors The coadministration of Bendamustine Hydrochloride Injection with CYP1A2 inhibitors may increase bendamustine plasma concentrations and may result in increased incidence of adverse reactions with Bendamustine Hydrochloride Injection [see Clinical Pharmacology (12.3) ] . (etykieta leku Bendamustyna, Interakcje z innymi lekami)
Consider alternative therapies that are not CYP1A2 inducers or inhibitors during treatment with Bendamustine Hydrochloride Injection. (etykieta leku Bendamustyna, Interakcje z innymi lekami)
Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Effect of Other Drugs on Bendamustine Hydrochloride Injection CYP1A2 Inhibitors The coadministration of Bendamustine Hydrochloride Injection with CYP1A2 inhibitors may increase bendamustine plasma concentrations and may result in increased incidence of adverse reactions with Bendamustine Hydrochloride Injection [see Clinical Pharmacology (12.3) ] . (etykieta leku Bendamustyna, Interakcje z innymi lekami)
Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)
Effect of Other Drugs on Bendamustine Hydrochloride Injection CYP1A2 Inhibitors The coadministration of Bendamustine Hydrochloride Injection with CYP1A2 inhibitors may increase bendamustine plasma concentrations and may result in increased incidence of adverse reactions with Bendamustine Hydrochloride Injection [see Clinical Pharmacology (12.3) ] . (etykieta leku Bendamustyna, Interakcje z innymi lekami)
Effect of Other Drugs on Bendamustine Hydrochloride Injection CYP1A2 Inhibitors The coadministration of Bendamustine Hydrochloride Injection with CYP1A2 inhibitors may increase bendamustine plasma concentrations and may result in increased incidence of adverse reactions with Bendamustine Hydrochloride Injection [see Clinical Pharmacology (12.3) ] . (etykieta leku Bendamustyna, Interakcje z innymi lekami)
Sprawdź, jak Bendamustyna łączy się ze wszystkim, co przyjmujesz. Dodaj całą listę; wszystkie pary są sprawdzane jednocześnie.
Otwórz w wyszukiwarceTo nie jest porada medyczna. Stopień nasilenia odzwierciedla sformułowania etykiety, a nie indywidualne okoliczności. Oznaczenie „poważna” może dotyczyć połączenia stosowanego rutynowo pod nadzorem, a „niewielka” może mieć znaczenie przy dużych dawkach. Należy zapytać farmaceutę.